Skip to NavigationSkip to content

Cancer Research UK appoints Professor Sir Bruce Ponder as trustee

Published on: 25/01/16

Cancer Research UK has appointed Professor Sir Bruce Ponder as a trustee.

Ponder is emeritus professor of oncology at Cambridge University. He was formerly Li Ka Shing professor of oncology, and founding director of the Cancer Research UK Cambridge Research Institute and of the Cambridge Cancer Centre. He was also co-director of both the Hutchison/MRC Research Centre and the Strangeways Research Laboratories for genetic epidemiology.

Sir Bruce trained in medicine in London and completed a PhD at the Imperial Cancer Research Fund ā€“ now known as the Cancer Research UK London Research Institute. He studied medical oncology at the Dana Farber Cancer Institute at Harvard University.

He was an early researcher in the genetics of susceptibility to cancer, establishing clinics to help families with a strong history of cancer, and identifying a gene for one type of familial thyroid cancer. With others, he set up the International Consortium that was behind the discovery of the BRCA1 and BRCA2 breast cancer genes and was its first chair. In 2007 his research group published the first cancer genome-wide association study in breast cancer.

Cancer Research UK chairman Michael Pragnell says: ā€œIā€™m very pleased to welcome Sir Bruce to our governing Council. He is an internationally renowned cancer researcher and his extensive knowledge and experience will be hugely valuable to the Charity. I much look forward to working with him.ā€

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches